A Phase 4 interventional study of Manzanilla Sophia® and Meticel Ofteno® 0.5% in Ophthalmological Agent Toxicity, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue.
Primary Objective:
Demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue.
Secondary Objectives:
Signs and Symptoms Evaluated:
Safety Assessment:
- Compare the incidence of adverse events (AEs) related to the interventions.
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matricaria recutita 0.025%. One drop four times per day (QID), with a minimun interval of 3 hours between administrations, for 7 days.
Drug: Manzanilla Sophia®
Hydroxypropyl methylcellulose 0.5%. One drop QID, with a minimun interval of 3 hours between administrations, for 7 days.
Drug: Meticel Ofteno® 0.5%
Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.
Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.
The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline
To demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue. Based on other tools previously used for the assessment of eye fatigue, the visual analog test for eye fatigue used in this protocol is adapted and created. This test includes the following questions: "Have you had a headache?", "Have you had eye strain?", "Do you have gritty sensation in your eyes?", "Have your eyes been itchy?", "How would you describe your clarity of sight?", "Do you feel any discomfort when you fix your eyes?". Each of these questions will be answered according to a Likert scale of 1-5. The sum of the answers, the total score, will be measured in a scale from 6 to 30. A higher score is a a worse outcome for this variable.
Time frame: Day 8 (Final visit)
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Red Eye
The presence of red eye (presence/absence) will be assessed based on direct observation by the investigator.
Time frame: Day 0 (Basal visit), Day 8 (Final visit)
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Dry Eye Sensation.
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
Time frame: Day 0 (Basal visit), Day 8 (Final visit)
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Eye Irritation
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
Time frame: Day 0 (Basal visit), Day 8 (Final visit)
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Sensation of Eye Discharge.
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
Time frame: Day 0 (Basal visit), Day 8 (Final visit)
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP).
This result was obtained by the principal investigator directly questioning the subject, and the response was recorded as present/absent.
Time frame: Day 8 (Final visit)
Comparison of the Incidence of Adverse Events (AEs) Related to the Interventions Between Groups
For this variable, only the number of adverse events classified as related to interventions in each group are compared.
Time frame: Day 0 (Basal visit), Day 8 (Final visit)
| Milestone | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Started | 84 | 83 |
| Completed | 83 | 81 |
| Not completed | 1 | 2 |
To demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue. Based on other tools previously used for the assessment of eye fatigue, the visual analog test for eye fatigue used in this protocol is adapted and created. This test includes the following questions: "Have you had a headache?", "Have you had eye strain?", "Do you have gritty sensation in your eyes?", "Have your eyes been itchy?", "How would you describe your clarity of sight?", "Do you feel any discomfort when you fix your eyes?". Each of these questions will be answered according to a Likert scale of 1-5. The sum of the answers, the total score, will be measured in a scale from 6 to 30. A higher score is a a worse outcome for this variable.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline | 74 | 72 |
The presence of red eye (presence/absence) will be assessed based on direct observation by the investigator.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Basal visit — Red eye | 15 | 9 |
| Basal visit — No red eye | 68 | 72 |
| Final visit — Red eye | 1 | 1 |
| Final visit — No red eye | 82 | 80 |
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Basal visit | 53 | 55 |
| Final visit | 10 | 8 |
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Basal visit | 54 | 54 |
| Final visit | 13 | 8 |
This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Basal visit | 32 | 38 |
| Final visit | 4 | 2 |
This result was obtained by the principal investigator directly questioning the subject, and the response was recorded as present/absent.
| Participants | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP). | 73 | 68 |
For this variable, only the number of adverse events classified as related to interventions in each group are compared.
| number of events | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Related | 48 | 45 |
| Unrelated | 3 | 4 |
Collected over The adverse events were recorded over an 11-day period, the duration of the clinical study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Manzanilla Sophia® | 0/84 (0%) | 0/84 (0%) | 35/84 (41.7%) |
| Meticel Ofteno® 0.5% | 0/83 (0%) | 0/83 (0%) | 35/83 (42.2%) |
| Event | Manzanilla Sophia® | Meticel Ofteno® 0.5% |
|---|---|---|
| Eye irritationEye disorders | 26/84 | 23/83 |
| Itching in the eyeEye disorders | 9/84 | 7/83 |
| Blurred visionEye disorders | 3/84 | 7/83 |
| Increased tearingEye disorders | 4/84 | 1/83 |
| HeadacheNervous system disorders | 4/84 | 1/83 |
| AsthenopiaEye disorders | 0/84 | 2/83 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/84 | 2/83 |
| Eye painEye disorders | 2/84 | 1/83 |
| DysgeusiaNervous system disorders | 1/84 | 1/83 |
| DengueInfections and infestations | 0/84 | 1/83 |
Demographic characteristics were analyzed in the intention-to-treat (ITT) population.
| Age, Continuous(years) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mean | 42.79 ± 15.0 | 41.91 ± 14.1 | 42.69 ± 14.8 |
| Sex: Female, Male(Participants) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Female | 53 | 54 | 107 |
| Male | 31 | 28 | 59 |
| Race and Ethnicity Not Collected(Participants) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mexico | 84 | 82 | 166 |
| Systolic blood pressure(millimeters of mercury (mmHg)) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mean | 112.77 ± 14.2 | 111.48 ± 11.2 | 112.18 ± 12.8 |
| Diastolic blood pressure(millimeters of mercury (mmHg)) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mean | 71.58 ± 7.4 | 71.05 ± 7.0 | 71.28 ± 7.2 |
| Heart rate(beats per minute) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mean | 73.64 ± 10.2 | 72.60 ± 10.6 | 73.04 ± 10.4 |
| Respiratory rate(breaths per minute) | Manzanilla Sophia® | Meticel Ofteno® 0.5% | Total |
|---|---|---|---|
| Mean | 18.1 ± 1.5 | 17.91 ± 1.6 | 17.98 ± 1.5 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2025 to primary completion in Sep 2025, 4 months.
Results were first posted in Apr 2026, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Sophia S.A de C.V. →